Login / Signup

Oncometabolite d-2HG alters T cell metabolism to impair CD8 + T cell function.

Giulia NotarangeloJessica Brooke SpinelliElizabeth M PerezGregory J BakerKiran KurmiIlaria EliaSylwia A StopkaGerard BaquerJia-Ren LinAlexandra J GolbyShakchhi JoshiHeide F BaronJefte M DrijversPeter GeorgievAlison E RingelElma ZaganjorSamuel K McBrayerPeter Karl SorgerArlene H SharpeKai W WucherpfennigSandro SantagataNathalie Y R AgarMario L SuvàMarcia C Haigis
Published in: Science (New York, N.Y.) (2022)
Gain-of-function mutations in isocitrate dehydrogenase (IDH) in human cancers result in the production of d-2-hydroxyglutarate (d-2HG), an oncometabolite that promotes tumorigenesis through epigenetic alterations. The cancer cell-intrinsic effects of d-2HG are well understood, but its tumor cell-nonautonomous roles remain poorly explored. We compared the oncometabolite d-2HG with its enantiomer, l-2HG, and found that tumor-derived d-2HG was taken up by CD8 + T cells and altered their metabolism and antitumor functions in an acute and reversible fashion. We identified the glycolytic enzyme lactate dehydrogenase (LDH) as a molecular target of d-2HG. d-2HG and inhibition of LDH drive a metabolic program and immune CD8 + T cell signature marked by decreased cytotoxicity and impaired interferon-γ signaling that was recapitulated in clinical samples from human patients with IDH1 mutant gliomas.
Keyphrases